Key Studies Influencing My Practice Following EACS 2021

October 27-30, 2021; London, United Kingdom
Read expert faculty members’ summaries of key studies from EACS 2021, including results from studies on BIC/FTC/TAF in a test-and-treat model; islatravir and doravirine in treatment naïve patients; DTG/3TC in patients with an M184V mutation; long-acting CAB + RPV by BMI category, patient satisfaction, and outcomes after discontinuation; lenacapavir in heavily treatment experienced patients; and COVID-19 vaccine effectiveness and the impact of the pandemic on virologic suppression in PWH.
Tristan J. Barber, MA, MD, FRCP
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Jürgen K. Rockstroh, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 697 KB
Released: November 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings